Lawrence Hamann

Lawrence Hamann

Company: Celgene

Job title: Corporate Vice President, Chemistry

Bio:

Larry Hamann is currently Corporate Vice President and Global Head of Chemistry at Celgene, with responsibility for Medicinal and Computational Chemistry, Biochemistry, Structural and Chemical Biology and Screening. In > 27 years of drug discovery experience he has led teams responsible for more than 16 clinical stage compounds, including the FDA approved DPP4 inhibitor saxagliptin (Onglyza™) for type 2 diabetes, and first-in-class HCV NS5A inhibitor daclatasvir (Daklinza™) for hepatitis C. At Celgene, his teams have advanced a number of molecules into the clinic in oncology and autoimmune disease. Prior to Celgene, Larry was Executive Director, Global Discovery Chemistry at Novartis, overseeing programs in oncology, neuroscience, respiratory, cardiovascular, and rare genetic disease. Among the compounds from these efforts that continue to advance in clinical trials are branaplam – an investigational Phase II oral drug for treatment of Spinal Muscular Atrophy, a rare and fatal genetic disease, and LSZ102 – a Selective Estrogen Receptor Degrader (SERD) for ER+ breast cancer. Previously, Larry was at Bristol-Myers Squibb and Ligand Pharmaceuticals. Larry is co-inventor on > 70 patents and co-author on > 75 scientific publications, and serves on the NIH Study Section for Synthetic and Biological Chemistry. Larry holds a BS in Chemistry from the University of Detroit and a PhD in Organic Chemistry from the University of Michigan.

Proud To Partner With

Expertise Partner:

Program Partner:

Innovation Partners:

Exhibition Partner:

 

Event Partner:

admin-ajax
Chemical Computing Group
UBIQUIGENT
Biodesy_Logo_NEW
BioTheryX
Life-Sensors
Bio-techne

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.